Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).
Since the rhesus is often used as a "gatekeeper" model for the evaluation of malaria and simian immunodeficiency virus (SIV)/HIV vaccines, the identification of strategies to enhance the activation of rhesus T cells would potentially aid in the generation of more potent vaccines directed against these infectious agents. Several molecules normally found on the surface of professional human APCs are capable of providing the second signals critical for T cell activation: B7-1 (CD80), ICAM-1 (CD54), and LFA-3 (CD58). With the exception of B7, T cell costimulatory molecules in the rhesus have not been identified. We have recently designed and characterized both recombinant vaccinia and recombinant avipox vectors containing the transgenes for a triad of human T cell costimulatory molecules (B7-1, ICAM-1, LFA-3; designated TRICOM). Here, we demonstrate the enhanced activation of rhesus T cells stimulated with rhesus APCs infected with TRICOM vectors in the presence of signal 1. Infection with TRICOM vectors led to significant improvement of APC capabilities in terms of reduction of the amount of signal 1 needed to activate naive T cells, and reduction in the amount of APCs required to activate T cells using a constant amount of signal 1. Antibody blocking studies demonstrated that each of the three costimulatory molecule transgenes contributed to the enhanced proliferation of T cells. TRICOM-enhanced T cell activation was shown to correspond to increases in type 1 cytokines and a reduced level of apoptosis. TRICOM-infected autologous B cells from rhesus immunized with either an SIV vaccine or a malaria vaccine stimulated significantly greater levels of IFN-gamma in response to specific peptide than stimulation with uninfected autologous B cells or B cells infected with wild-type vector. The ability to augment immune responses using poxvirus-based vaccines containing multiple costimulatory molecule transgenes can now be addressed in the rhesus macaque model.
Shankar
P
P
Research Scholar's Program at the NIH, Howard Hughes Medical Institute, Bethesda, MD 20892, USA.
Schlom
J
J
Hodge
J W
JW
D016915:AIDS Vaccines / Q000235:genetics; D000818:Animals; D018150:Avipoxvirus / Q000235:genetics; D018122:B7-1 Antigen / Q000008:administration & dosage / Q000235:genetics*; D018968:CD58 Antigens / Q000008:administration & dosage / Q000235:genetics*; D002460:Cell Line; D016207:Cytokines / Q000096:biosynthesis; D015870:Gene Expression; D005822:Genetic Vectors; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000008:administration & dosage / Q000235:genetics*; D007371:Interferon-gamma / Q000096:biosynthesis; D008024:Ligands; D008213:Lymphocyte Activation; D008253:Macaca mulatta; D008288:Malaria / Q000276:immunology; D018449:SAIDS Vaccines / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology*; D014616:Vaccinia virus / Q000235:genetics
D016915:AIDS Vaccines; D018122:B7-1 Antigen; D018968:CD58 Antigens; D016207:Cytokines; D008024:Ligands; D018449:SAIDS Vaccines; D018799:Intercellular Adhesion Molecule-1; D007371:Interferon-gamma